Gastroenteropancreatic Neuroendocrine Tumors
Oncology
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
3100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
IpsenChina - Tianjin
4 programs2
1
Lanreotide Autogel 120 mgPhase 2Peptide1 trial
LanreotidePhase 1/2Peptide
satoreotide trizoxetanPhase 1/2Peptide1 trial
Community-based Neuroendocrine Tumor (NET) Research StudyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
IpsenLanreotide Autogel 120 mg
Ipsensatoreotide trizoxetan
IpsenCommunity-based Neuroendocrine Tumor (NET) Research Study
Clinical Trials (3)
Total enrollment: 169 patients across 3 trials
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Start: Oct 2014Est. completion: Jun 201757 patients
Phase 2Completed
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Start: Jun 2014Est. completion: Jun 201512 patients
Phase 1/2Completed
Community-based Neuroendocrine Tumor (NET) Research Study
Start: Nov 2015Est. completion: May 2020100 patients
N/ACompleted
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
6m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
6m ago
Office Administrator
SystImmune
7m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
17m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
20m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
20m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Peptide is the dominant modality (100% of programs)
1 companies competing in this space